The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Emerging concepts of miRNA therapeutics: from cells to clinic
Open accessAbstract
MicroRNAs (miRNAs) are very powerful genetic regulators, as evidenced by the fact that a single miRNA can direct entire cellular pathways via interacting with a broad spectrum of target genes. This property renders miRNAs as highly interesting therapeutic tools to restore cell functions that are altered as part of a disease phenotype. However, this strength of miRNAs is also a weakness because their cellular effects are so numerous that off-target effects can hardly be avoided. In this review, we point out the main challenges and the strategies to specifically address the problems that need to be surmounted in the push toward a therapeutic application of miRNAs. Particular emphasis is given to approaches that have already found their way into clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
miRBase: from microRNA sequences to function
Kozomara, A., Birgaoanu, M., & Griffiths-Jones, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1141 · Cited by 4,843
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796
Many roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Regulation of microRNA function in animals
Gebert, L. F. R., & MacRae, I. J. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0045-7 · Cited by 2,284
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
The biochemical basis of microRNA targeting efficacy
(2019) · doi:10.1126/science.aav1741 · Cited by 1,570
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database
Huang, H.-Y., Lin, Y.-C.-D., Li, J., Huang, K.-Y., Shrestha, S., Hong, H.-C., Tang, Y., Chen, Y.-G., Jin, C.-N., Yu, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz896 · Cited by 1,259
Zhang, L., Hou, D., Chen, X., Li, D., Zhu, L., Zhang, Y., Li, J., Bian, Z., Liang, X., Cai, X., et al. (2012) · Cell Research · doi:10.1038/cr.2011.158 · Cited by 1,216
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,197
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Distribution of miRNA expression across human tissues
Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Rheinheimer, S., Meder, B., Stähler, C., Meese, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw116 · Cited by 968
Self-citationRecent advances in biomaterials for 3D scaffolds: A review
Nikolova, M. P., & Chavali, M. S. (2019) · Bioactive Materials · doi:10.1016/j.bioactmat.2019.10.005 · Cited by 907
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology
Chang, L., Zhou, G., Soufan, O., & Xia, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa467 · Cited by 880
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
mirDIP 4.1—integrative database of human microRNA target predictions
Tokar, T., Pastrello, C., Rossos, A. E. M., Abovsky, M., Hauschild, A.-C., Tsay, M., Lu, R., & Jurisica, I. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1144 · Cited by 572
An estimate of the total number of true human miRNAs
Alles, J., Fehlmann, T., Fischer, U., Backes, C., Galata, V., Minet, M., Hart, M., Abu-Halima, M., Grässer, F. A., Lenhof, H.-P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz097 · Cited by 567
Self-citationTransfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534
Life of RISC: Formation, action, and degradation of RNA-induced silencing complex
Iwakawa, H.-O., & Tomari, Y. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.11.026 · Cited by 488
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis
Licursi, V., Conte, F., Fiscon, G., & Paci, P. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3105-x · Cited by 401
Täubel, J., Hauke, W., Rump, S., Viereck, J., Batkai, S., Poetzsch, J., Rode, L., Weigt, H., Genschel, C., Lorch, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa898 · Cited by 393
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 368
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
Gong, C., Tian, J., Wang, Z., Gao, Y., Wu, X., Ding, X., Qiang, L., Li, G., Han, Z., Yuan, Y., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0526-7 · Cited by 339
Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer
Liu, H., Lei, C., He, Q., Pan, Z., Xiao, D., & Tao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0765-5 · Cited by 336
Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333
Recent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 307
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Gallant-Behm, C. L., Piper, J., Lynch, J. M., Seto, A. G., Hong, S. J., Mustoe, T. A., Maari, C., Pestano, L. A., Dalby, C. M., Jackson, A. L., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.007 · Cited by 278
Genomic organization of microRNAs
Olena, A. F., & Patton, J. G. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21993 · Cited by 275
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Lack of detectable oral bioavailability of plant microRNAs after feeding in mice
Dickinson, B., Zhang, Y., Petrick, J. S., Heck, G., Ivashuta, S., & Marshall, W. S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2737 · Cited by 268
Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects
Zhang, X., Li, Y., Chen, Y. E., Chen, J., & Ma, P. X. (2016) · Nature Communications · doi:10.1038/ncomms10376 · Cited by 268
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 253
Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs
Disney, M. D., Winkelsas, A. M., Velagapudi, S. P., Southern, M., Fallahi, M., & Childs-Disney, J. L. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00001 · Cited by 248
miRPathDB 2.0: a novel release of the miRNA Pathway Dictionary Database
Kehl, T., Kern, F., Backes, C., Fehlmann, T., Stöckel, D., Meese, E., Lenhof, H.-P., & Keller, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz1022 · Cited by 246
Self-citationReid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., & van Zandwijk, N. (2016) · Epigenomics · doi:10.2217/epi-2016-0035 · Cited by 242
miRNA Targets: From Prediction Tools to Experimental Validation
Riolo, G., Cantara, S., Marzocchi, C., & Ricci, C. (2020) · Methods and Protocols · doi:10.3390/mps4010001 · Cited by 239
MicroRNAs: biomarkers, diagnostics, and therapeutics
Huang, W. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7046-9_4 · Cited by 237
Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Recombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Zhang, S., Cheng, Z., Wang, Y., & Han, T. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s288859 · Cited by 211
miRTargetLink 2.0—interactive miRNA target gene and target pathway networks
Kern, F., Aparicio-Puerta, E., Li, Y., Fehlmann, T., Kehl, T., Wagner, V., Ray, K., Ludwig, N., Lenhof, H.-P., Meese, E., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab297 · Cited by 205
Self-citationmiEAA 2.0: integrating multi-species microRNA enrichment analysis and workflow management systems
Kern, F., Fehlmann, T., Solomon, J., Schwed, L., Grammes, N., Backes, C., Van Keuren-Jensen, K., Craig, D. W., Meese, E., & Keller, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa309 · Cited by 197
Self-citationTransfection of microRNA Mimics Should Be Used with Caution
Jin, H. Y., Gonzalez-Martin, A., Miletic, A. V., Lai, M., Knight, S., Sabouri-Ghomi, M., Head, S. R., Macauley, M. S., Rickert, R. C., & Xiao, C. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00340 · Cited by 192
Lavenniah, A., Luu, T. D. A., Li, Y. P., Lim, T. B., Jiang, J., Ackers-Johnson, M., & Foo, R. S.-Y. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.006 · Cited by 175
Lai, X., Eberhardt, M., Schmitz, U., & Vera, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz638 · Cited by 170
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J., & Brown, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0209 · Cited by 168
Locked Nucleic Acid Oligonucleotides: The Next Generation of Antisense Agents?
Gr??nweller, A., & Hartmann, R. K. (2007) · BioDrugs · doi:10.2165/00063030-200721040-00004 · Cited by 164
Gallant‐Behm, C. L., Piper, J., Dickinson, B. A., Dalby, C. M., Pestano, L. A., & Jackson, A. L. (2018) · Wound Repair and Regeneration · doi:10.1111/wrr.12660 · Cited by 164
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study
Abplanalp, W. T., Fischer, A., John, D., Zeiher, A. M., Gosgnach, W., Darville, H., Montgomery, R. L., Pestano, L. A., Allée, G., Paty, I., et al. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0871 · Cited by 164
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure
Bátkai, S., Genschel, C., Viereck, J., Rump, S., Bär, C., Borchert, T., Traxler, D., Riesenhuber, M., Spannbauer, A., Lukovic, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa791 · Cited by 163
Kashtan, C. E., & Gross, O. (2021) · Pediatric Nephrology · doi:10.1007/s00467-020-04819-6 · Cited by 162
Miniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E. S., Martier, R., Koornneef, A., Southwell, A. L., Hayden, M. R., van Deventer, S. J. H., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.7 · Cited by 143
Improving siRNA Delivery In Vivo Through Lipid Conjugation
Osborn, M. F., & Khvorova, A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0725 · Cited by 137
Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy
Rappaport, J., Hanss, B. G., Kopp, J. B., Copeland, T. D., Bruggeman, L. A., Coffman, T. M., & Klotman, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.205 · Cited by 132
Plant MicroRNAs—Novel Players in Natural Medicine?
Łukasik, A., & Zielenkiewicz, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010009 · Cited by 119
Inhaled RNA Therapy: From Promise to Reality
Chow, M. Y. T., Qiu, Y., & Lam, J. K. W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.002 · Cited by 117
Tosar, J. P., Rovira, C., Naya, H., & Cayota, A. (2014) · RNA · doi:10.1261/rna.044263.114 · Cited by 116
A general fragment-based approach to identify and optimize bioactive ligands targeting RNA
Suresh, B. M., Li, W., Zhang, P., Wang, K. W., Yildirim, I., Parker, C. G., & Disney, M. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012217117 · Cited by 104
Grimm, D. (2011) · Silence · doi:10.1186/1758-907x-2-8 · Cited by 100
GeneTrail 3: advanced high-throughput enrichment analysis
Gerstner, N., Kehl, T., Lenhof, K., Müller, A., Mayer, C., Eckhart, L., Grammes, N. L., Diener, C., Hart, M., Hahn, O., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa306 · Cited by 100
Self-citationArtificial miRNAs as therapeutic tools: Challenges and opportunities
Kotowska‐Zimmer, A., Pewińska, M., & Olejniczak, M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1640 · Cited by 99
Off‐Target Effects Related to the Phosphorothioate Modification of Nucleic Acids
Winkler, J., Stessl, M., Amartey, J., & Noe, C. R. (2010) · ChemMedChem · doi:10.1002/cmdc.201000156 · Cited by 96
Seo, H. A., Moeng, S., Sim, S., Kuh, H. J., Choi, S. Y., & Park, J. K. (2019) · Cells · doi:10.3390/cells9010029 · Cited by 95
Ji, Y., Fioravanti, J., Zhu, W., Wang, H., Wu, T., Hu, J., Lacey, N. E., Gautam, S., Gall, J. B. L., Yang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09882-8 · Cited by 93
3D Printed Drug Delivery Systems Based on Natural Products
Aguilar-de-Leyva, Á., Linares, V., Casas, M., & Caraballo, I. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070620 · Cited by 92
Shu, J., Xia, Z., Li, L., Liang, E. T., Slipek, N. J., Shen, D., Foo, J., Subramanian, S., & Steer, C. J. (2012) · RNA Biology · doi:10.4161/rna.21998 · Cited by 90
Monahan, P. E., Négrier, C., Tarantino, M. D., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 90
Tools4miRs – one place to gather all the tools for miRNA analysis
Łukasik, A., Wójcikowski, M., & Zielenkiewicz, P. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw189 · Cited by 86
Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors
Herrera-Carrillo, E., Liu, Y. P., & Berkhout, B. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.036 · Cited by 86
Validation of human microRNA target pathways enables evaluation of target prediction tools
Kern, F., Krammes, L., Danz, K., Diener, C., Kehl, T., Küchler, O., Fehlmann, T., Kahraman, M., Rheinheimer, S., Aparicio‐Puerta, E., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1161 · Cited by 86
Self-citationSamaranch, L., Blits, B., Sebastián, W. S., Hadaczek, P., Bringas, J., Sudhakar, V. R., Macayan, M., Pivirotto, P., Petry, H., & Bankiewicz, K. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.14 · Cited by 85
Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
Biessen, E. A. L., Vietsch, H., Rump, E. T., Fluiter, K., Kuiper, J., Bijsterbosch, M. K., & van Berkel, T. J. C. (1999) · Biochemical Journal · doi:10.1042/bj3400783 · Cited by 82
miTALOS v2: Analyzing Tissue Specific microRNA Function
Preusse, M., Theis, F. J., & Mueller, N. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151771 · Cited by 80
Dietary plant miRNAs as an augmented therapy: cross-kingdom gene regulation
Sanchita, Trivedi, R., Asif, M. H., & Trivedi, P. K. (2018) · RNA Biology · doi:10.1080/15476286.2018.1551693 · Cited by 77
microRNA-34a as a Therapeutic Agent against Human Cancer
Saito, Y., Nakaoka, T., & Saito, H. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4111951 · Cited by 76
Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates
Kelnar, K., Peltier, H. J., Leatherbury, N., Stoudemire, J., & Bader, A. G. (2014) · Analytical Chemistry · doi:10.1021/ac403044t · Cited by 75
Keskin, S., Brouwers, C. C., Sogorb-González, M., Martier, R., Depla, J. A., Vallès, A., van Deventer, S. J. H., Konstantinova, P. S., & Evers, M. M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.010 · Cited by 73
Deprey, K. L., Batistatou, N., & Kritzer, J. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa576 · Cited by 73
Drenth, J. P. H., & Schattenberg, J. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1839888 · Cited by 73
Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer
Norouzi, S., Majeed, M. A., Pirro, M., Generali, D., & Sahebkar, A. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666171129203506 · Cited by 71
miR-146b antagomir–treated human Tregs acquire increased GVHD inhibitory potency
Lu, Y., Hippen, K. L., Lemire, A. M., Gu, J., Wang, W., Ni, X., Ranganathan, P., Levine, B. L., Riley, J. L., June, C. H., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714535 · Cited by 70
Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics
Fan, R., Xiao, C., Wan, X., Cha, W., Miao, Y., Zhou, Y., Qin, C., Cui, T., Su, F., & Shan, X. (2019) · RNA Biology · doi:10.1080/15476286.2019.1593094 · Cited by 69
Narayan, N., Morenos, L., Phipson, B., Willis, S. N., Brumatti, G., Eggers, S., Lalaoui, N., Brown, L. M., Kosasih, H. J., Bartolo, R. C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.279 · Cited by 67
Miller, C. M., Tanowitz, M., Donner, A. J., Prakash, T. P., Swayze, E. E., Harris, E. N., & Seth, P. P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0709 · Cited by 65
Kardani, A., Yaghoobi, H., Alibakhshi, A., & Khatami, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29584 · Cited by 65
Cross-Kingdom Regulation by Plant microRNAs Provides Novel Insight into Gene Regulation
Samad, A. F. A., Kamaroddin, M. F., & Sajad, M. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa095 · Cited by 64
Baldari, S., Rocco, G. D., Magenta, A., Picozza, M., & Toietta, G. (2019) · Cells · doi:10.3390/cells8121560 · Cited by 63
Meng, L., Chang, S., Sang, Y., Ding, P., Wang, L., Nan, X., Xu, R., Liu, F., Gu, L., Zheng, Y., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-021-01497-6 · Cited by 60
Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells
Russo, V. M., Paciocco, A., Affinito, A., Roscigno, G., Fiore, D., Palma, F., Galasso, M., Volinia, S., Fiorelli, A., Esposito, C. L., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.016 · Cited by 58
Stelma, F., van der Ree, M. H., Sinnige, M. J., Brown, A., Swadling, L., de Vree, J. M. L., Willemse, S. B., van der Valk, M., Grint, P., Neben, S., et al. (2017) · Hepatology · doi:10.1002/hep.29148 · Cited by 55
miR-34a as hub of T cell regulation networks
Hart, M., Walch‐Rückheim, B., Krammes, L., Kehl, T., Rheinheimer, S., Tänzer, T., Glombitza, B., Sester, M., Lenhof, H., Keller, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0670-5 · Cited by 51
Self-citationQuerfeld, C., Pacheco, T. R., Foss, F. M., Halwani, A. S., Porcu, P., Seto, A. G., Ruckman, J., Landry, M. L., Jackson, A. L., Pestano, L. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1829.1829 · Cited by 51
Hart, M., Nickl, L., Walch‐Rückheim, B., Krammes, L., Rheinheimer, S., Diener, C., Tänzer, T., Kehl, T., Sester, M., Lenhof, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001617 · Cited by 51
Self-citationWhat’s the target: understanding two decades of in silico microRNA-target prediction
Kern, F., Backes, C., Hirsch, P., Fehlmann, T., Hart, M., Meese, E. U., & Keller, A. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz111 · Cited by 50
Self-citation3D Printed Bioconstructs: Regenerative Modulation for Genetic Expression
Shende, P. K., & Trivedi, R. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10120-2 · Cited by 50
Jivrajani, M. N., & Nivsarkar, M. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.06.004 · Cited by 43
miR‐155expression in antitumor immunity: The higher the better?
Michaille, J., Awad, H., Fortman, E. C., Efanov, A. A., & Tili, E. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22698 · Cited by 43
Special Issue: MicroRNA Regulation in Health and Disease
Subramanian, S., & Steer, C. J. (2019) · Genes · doi:10.3390/genes10060457 · Cited by 42
Laczny, C. C., Leidinger, P., Haas, J., Ludwig, N., Backes, C., Gerasch, A., Kaufmann, M., Vogel, B., Katus, H. A., Meder, B., et al. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-36 · Cited by 41
Self-citationEnhancing adoptive T cell immunotherapy with microRNA therapeutics
Ji, Y., Hocker, J. D., & Gattinoni, L. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.006 · Cited by 41
Modulation of intracellular calcium signaling by microRNA-34a-5p
Diener, C., Hart, M., Alansary, D., Poth, V., Walch‐Rückheim, B., Menegatti, J., Grässer, F. A., Fehlmann, T., Rheinheimer, S., Niemeyer, B. A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1050-7 · Cited by 32
Self-citationBioengineering of a single long noncoding RNA molecule that carries multiple small RNAs
Petrek, H. E., Batra, N., Ho, P. Y., Tu, M., & Yu, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09934-5 · Cited by 31
Targeting micro-RNAs by natural products: a novel future therapeutic strategy to combat cancer.
Alnuqaydan, A. M. (2020) · PubMed · Cited by 30
Quantitative and time-resolved miRNA pattern of early human T cell activation
Diener, C., Hart, M., Kehl, T., Rheinheimer, S., Ludwig, N., Krammes, L., Pawusch, S., Lenhof, K., Tänzer, T., Schub, D., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa788 · Cited by 29
Self-citationExperimental MicroRNA Detection Methods
Yaylak, B., & Akgül, B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1170-8_2 · Cited by 29
Katoh, S., Yoshioka, H., Senthilkumar, R., Preethy, S., & Abraham, S. J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119553 · Cited by 25
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
Yamamoto, T., Mukai, Y., Wada, F., Terada, C., Kayaba, Y., Oh, K., Yamayoshi, A., Obika, S., & Harada‐Shiba, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060817 · Cited by 24
A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic
Kelnar, K., & Bader, A. G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_8 · Cited by 23
Plant microRNAs in human sera are likely contaminants
Fromm, B., Kang, W., Rovira, C., Cayota, A., Witwer, K. W., Friedländer, M. R., & Tosar, J. P. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.019 · Cited by 21
New technologies for improved relevance in miRNA research
Jacquet, K., Vidal-Cruchez, O., Rezzonico, R., Nicolini, V. J., Mograbi, B., Hofman, P. M., Vassaux, G., Mari, B. P., & Brest, P. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.006 · Cited by 15
miRViz: a novel webserver application to visualize and interpret microRNA datasets
Giroux, P., Bhajun, R., Segard, S., Picquenot, C., Charavay, C., Desquilles, L., Pinna, G., Ginestier, C., Denis, J., Cherradi, N., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa259 · Cited by 14
Comment on: “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”
Zhang, S., & Zhu, F. (2021) · Drugs · doi:10.1007/s40265-021-01582-2 · Cited by 12
Sindhu, K. J., Venkatesan, N., & Karunagaran, D. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0087 · Cited by 11
Backes, C., Ludwig, N., Leidinger, P., Huwer, H., Tenzer, S., Fehlmann, T., Franke, A., Meese, E. U., Lenhof, H., & Keller, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11723 · Cited by 10
Self-citationJames, A. M., Ruckman, J., Pestano, L. A., HOPKINS, R., Rodgers, R., Marshall, W. S., Rubin, P. D., & Escolar, D. M. (2019) · Hematological Oncology · doi:10.1002/hon.10_2632 · Cited by 10
Cited by
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
The miRNA–target interactions: An underestimated intricacy
Diener, C., Keller, A., & Meese, E. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad1142 · Cited by 248
Self-citationExtracellular vesicles: New horizons in neurodegeneration
Chen, J., Tian, C., Xiong, X., Yang, Y., & Zhang, J. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105605 · Cited by 53
Progress in circRNA-Targeted Therapy in Experimental Parkinson’s Disease
(2023) · doi:10.3390/pharmaceutics15082035 · Cited by 26
Metadata
- Authors
- Diener, C., Keller, A., & Meese, E.
- Venue
- Trends in Genetics
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 38
- Issue
- 6
- Pages
- 613-626
- ISSN
- 0168-9525 (ISSN-L)
- OpenAlex
- W4220723100
- Cited by
- 971
- References
- 133
- FWCI
- 29.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.